Sundry Photography/iStock Editorial via Getty Images Merck’s ( NYSE: MRK ) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat two new indications in gynecologic cancers. The first approval is for Keytruda, in combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or.
Back to Health Page
